Papers by Carlos Martínez-Rivera
Annals of medicine (Helsinki)/Annals of medicine, Feb 16, 2024
Bookmarks Related papers MentionsView impact
Archivos de Bronconeumología
Bookmarks Related papers MentionsView impact
Medicina Clinica, Apr 1, 2018
Bookmarks Related papers MentionsView impact
COPD: Journal of Chronic Obstructive Pulmonary Disease, Feb 23, 2012
Anemia is a recognized prognostic factor in many chronic illnesses, but there is limited informat... more Anemia is a recognized prognostic factor in many chronic illnesses, but there is limited information about its impact on outcomes in patients hospitalized for acute COPD exacerbation (AECOPD). To investigate whether anemia exerts an effect on mortality in patients admitted for AECOPD after one year of follow-up. Methods. From November 2007 to November 2009 we recruited 117 patients who required hospitalization due to an AECOPD. Clinical, functional and laboratory parameters on admission were prospectively assessed. Patients were followed up during one year. Mortality and days-to-death were collected. Mean age 72 (SD ± 9); FEV₁ 37.4 (SD ± 12); mortality after 1 year was 22.2%. Mean survival: 339 days. Comparing patients who died to those who survived we found significant differences (p < 0,000) in hemoglobin (Hb) (12.4 vs 13.8 mg/dl) and hematocrit (Ht) (38 vs 41%). Anemia (Hb < 13 g.dl⁻¹) prevalence was 33%. Those who died had experienced 3.5 exacerbations in previous year vs 1.5 exacerbations in the case of the survivors (p = 0.000). Lung function and nutritional status were similar, except for percentage of muscle mass (%) (35 vs 39%; p = 0.015) and albumin (33 vs 37 mg/dl; p = 0.039). These variables were included in a Multivariate Cox Proportional Hazards Model; anemia and previous exacerbations resulted as independent factors for mortality. Mortality risk for patients with anemia was 5.9(CI: 1.9-19); for patients with > 1 exacerbation in the previous year was 5.9(CI: 1.3-26.5). Anemia and previous exacerbations were independent predictors of mortality after one year in patients hospitalized for AECOPD.
Bookmarks Related papers MentionsView impact
Karger Kompass, 2021
Bookmarks Related papers MentionsView impact
BMC Pulmonary Medicine, Jan 21, 2021
Bookmarks Related papers MentionsView impact
COPD: Journal of Chronic Obstructive Pulmonary Disease, Dec 16, 2016
Bookmarks Related papers MentionsView impact
Obesity, 2008
Background: Optimization of the indications for nocturnal polysomnography in the diagnosis of obs... more Background: Optimization of the indications for nocturnal polysomnography in the diagnosis of obstructive sleep apnea syndrome (OSAS) could lead to significant reductions in health expenditure. To this end, we assessed the usefulness of truncal obesity measurements in the diagnosis of OSAS.Methods and Procedures: One hundred ninety‐two patients (152 men and 40 women) referred to our clinic with suspected OSAS underwent a complete polysomnography study and their BMI and truncal obesity measurements were obtained.Results: Comparison of patients defined as snorers with OSAS patients, by means of the Student's t ‐test revealed significant differences in the truncal obesity parameters such as waist‐to‐hip ratio (0.94 vs. 0.98) and waist circumference (100.7 cm vs. 106.3 cm). We found no significant differences between BMI values in the two groups. Indices of truncal obesity were analyzed as predictive factors for OSAS using a multivariate logistic regression model that included variable sex, and in which waist‐to‐hip ratio, BMI, neck circumference, and age were analyzed as binary variables. According to this model, our patients' risk of suffering from OSAS was 2.6 times greater if the waist‐to‐hip ratio was >1 in men and >0.85 in women. The risk of OSAS was also increased if the patients were men or over 52 years of age.Discussion: Obtaining simple measurements such as those for truncal obesity may help prioritize the use of polysomnography in patients with a greater risk of OSAS. Our results suggest that BMI is not a good predictor of OSAS in a group of patients with a high BMI.
Bookmarks Related papers MentionsView impact
Medicina Clinica, May 1, 2019
Bookmarks Related papers MentionsView impact
The Journal of Allergy and Clinical Immunology: In Practice
Bookmarks Related papers MentionsView impact
Pulmonology
Bookmarks Related papers MentionsView impact
Respiratory Research
Background The ORBE II study aimed to describe the characteristics and clinical outcomes of adult... more Background The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain. Methods ORBE II (NCT04648839) was an observational, retrospective cohort study in adult SEA patients who had been prescribed benralizumab. Demographic and clinical data of 204 SEA patients were collected 12 months prior to benralizumab initiation (baseline) and at follow-up. Exacerbation rate, asthma symptoms, maintenance oral corticosteroid (OCS) use and lung function were evaluated, among other variables. Results A total of 204 SEA patients were evaluated. Mean (standard deviation, SD) age of the study population was 56.4 (12.4) years, 62.3% were women and mean (SD) duration of asthma was 15.1 (12.7) years. Median (Q1–Q3) follow-up duration was 19.5 (14.2–24.2) months. At baseline, 72.6% of the overall population (OP) presented blood eosinophil counts ≥ 300 cells/µL; 36.8% had co...
Bookmarks Related papers MentionsView impact
Airway pharmacology and treatment
Bookmarks Related papers MentionsView impact
Respiratory Medicine, Dec 1, 2012
Bookmarks Related papers MentionsView impact
Bookmarks Related papers MentionsView impact
European Respiratory Journal, Sep 1, 2013
Introduction: Mesenchymal stem cells (MSC)s have immunomodulatory properties and reduce airway in... more Introduction: Mesenchymal stem cells (MSC)s have immunomodulatory properties and reduce airway inflammation in experimental asthma. However, potential uses of MSCs for asthma therapies are challenged by the evidence that airway smooth muscle remodeling may in part occur through the recruitment and differentiation of fibrocytes, a bone marrow-derived progenitor cell of myeloid lineage. Aims and objectives: Here we tested if Stro-1, a marrow stromal MSC marker not expressed by hematopoietic cells, is present in airway smooth muscle. Methods: Bronchial biopsies from severe asthmatics (n=8) and non-asthmatic controls (n=4) were immunostained using monoclonal mouse IgM Stro-1 clone. Airway smooth muscle mass was measured as smooth muscle surface area, digitally extracted from hematoxylin & eosin stained sections, referenced to biopsy area (dimensionless). Data analysis was done with Mann-Whitney's U test. Results: Asthmatics had increased airway smooth muscle mass (0.68 ± 0.04 versus 0.24 ± 0.02 for controls, mean ± standard error, P = 0.007). Stro-1, present in airway smooth muscle as spotted antigen clusters, was increased in asthmatics (2.37 ± 0.76 versus 0.25 ± 0.14, clusters/mm2, P = 0.028). Conclusions: The data suggest that different progenitor cell populations may be recruited during airway smooth muscle remodeling in asthma, and cells of stromal MSC origin may be involved. Further research and solid preclinical development are warranted for MSC-based asthma therapies. Funded by FIS, SEPAR, FUCAP.
Bookmarks Related papers MentionsView impact
Research Square (Research Square), Dec 1, 2020
Bookmarks Related papers MentionsView impact
Respiratory Care, Aug 26, 2014
Bookmarks Related papers MentionsView impact
International Journal of Clinical Practice, May 16, 2013
Bookmarks Related papers MentionsView impact
International Journal of Chronic Obstructive Pulmonary Disease
Bookmarks Related papers MentionsView impact
Uploads
Papers by Carlos Martínez-Rivera